Series Part 3—Methods for early detection of risk and summary.
Strategies for sponsors in navigating the European Union's new health technology assessment regulation.
Bolstered by the recently approved S7B/E14 Q&A document, early-stage concentration-QTc analysis is emerging as a standard for assessing cardiac safety.
Lessons learned during the pandemic from University of Louisville.
The adaptability and innovative capacity of CROs highlighted in EUCROF survey.
Siloed systems can make it difficult to marry data to support timely and informed decision-making and optimize clinical trial operations.
Which new developments can help jump-start breakthroughs in immuno-oncology research? Understand the key scientific drivers, read peer-reviewed research, and get actionable ideas that can spur innovation in this must-read paper for clinical leaders.
Higher costs headline list of new challenges faced by CROs and sponsors.
Simultaneous and niche skills sought amid evolution in clinical data management.
Competency-based and other creative approaches are needed to address the battle for talent in the clinical research workforce.
With the number of clinical trials and sponsors increasing every year, meeting enrollment requirements and timelines becomes harder and harder. Please join Almac Clinical Technologies and Exostar as they discuss solutions to attract and retain the right resources to meet your requirements and timelines. Live: Thursday, Aug. 27, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Aug. 27, 2021.
Jon Ernst (Vice President, In-Home Solutions, Decentralized Clinical Trials) discusses today's clinical trial landscape.
Webinar Date/Time: This event is available on demand
A shared partnership culture is critical in navigating today’s complex terrain.
Although executive enthusiasm for decentralization of clinical trials has grown significantly, operationalizing these models requires meticulous planning and risk-based quality management.
Strategies for ensuring that innovation with PROs remains parallel with advancements in disease detection and progression.
While the world focuses on COVID-19, this article provides insight on the current state of the market for antimicrobial resistant (AMR) medicines.
Multicentric studies on diarrhea are essential for comprehending its epidemiology, causes, and treatment outcomes.
Successful oncolytic virus immunotherapy clinical development requires unique features that focus on viral biology and host immune response.
A framework to understand the different approaches of trial matching solutions and the major operational and workflow challenges that all matching solutions share.
FDA approves COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax targeting the LP.8.1 sublineage of SARS-CoV-2, with eligibility limited to adults aged 65 years and older and those with underlying medical conditions that place them with a high risk for severe disease.
Tufts CSDD study breaks down state of the talent pipeline from lens of senior leaders.
David MacMurchy, Chief Executive Officer at Lightship, offers some insights into the company's mission toward improving equity and diversity in clinical trials.
Identifying the ‘significant six’ areas of clinical study conduct to mitigate risk.
A discussion of the regulatory history behind audit trails and its interpretation as it relates to clinical research data originating or residing in EDC or eCOA systems.
How the digital environment can transform drug development space.